/SXTP
SXTP Stock - 60 Degrees Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$0.76-9.59%
$0.08 (-9.59%) • Dec 19
36
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.7
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.83
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SXTP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.75 – $0.77
TARGET (TP)$0.87
STOP LOSS$0.70
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.82
52W High$8.00
52W Low$0.75
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $607,574 | $253,573 | $223,208 | $1.16M | $2.18M |
| Gross Profit | $222,809 | $-220,977 | $-209,162 | $309,598 | $1.48M |
| Gross Margin | 36.7% | -87.1% | -93.7% | 26.7% | 67.8% |
| Operating Income | $-9,714,931 | $-5,154,583 | $-1,750,445 | $-1,124,102 | $-418,130 |
| Net Income | $-7,947,107 | $-3,765,702 | $-6,181,720 | $-4,251,745 | $-3,033,744 |
| Net Margin | -1308.0% | -1485.1% | -2769.5% | -366.4% | -139.1% |
| EPS | $-18.55 | $-0.95 | $-1.07 | $-0.74 | $-0.52 |
Company Overview
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SXTPBeat Rate
0%
Last 9 quarters
Avg Surprise
-53.6%
EPS vs Estimate
Beats / Misses
0/9
Last 12 quarters
Latest EPS
$-0.66
Q4 2025
EPS Surprise History
Q1 24
-24.8%
$-0.34vs$-0.27
Q2 24
-62.9%
$-26.41vs$-16.21
Q3 24
-6.8%
$-21.15vs$-19.80
Q4 24
-55.0%
$-4.65vs$-3.00
Q1 25
-254.1%
$-14.20vs$-4.01
Q2 25
-19.1%
$-1.56vs$-1.31
Q3 25
-0.8%
$-1.25vs$-1.24
Q4 25
-43.5%
$-0.66vs$-0.46
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.57 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.46 | $-0.66 | -43.5% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-1.24 | $-1.25 | -0.8% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-1.31 | $-1.56 | -19.1% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-4.01 | $-14.20 | -254.1% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-3.00 | $-4.65 | -55.0% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-19.80 | $-21.15 | -6.8% | ✗ MISS |
Q2 2024 | Apr 1, 2024 | $-16.21 | $-26.41 | -62.9% | ✗ MISS |
Q1 2024 | Mar 25, 2024 | $-0.27 | $-0.34 | -24.8% | ✗ MISS |
Q4 2023 | Nov 20, 2023 | $-15.61 | $-18.01 | -15.4% | ✗ MISS |
Q3 2023 | Aug 25, 2023 | — | $-1.40 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.47 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.35 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.26 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.39 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.16 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.23 | — | — |
Latest News
Ascendiant Capital Maintains Buy on 60 Degrees, Lowers Price Target to $2.8
➖ NeutralBenzinga•Nov 28, 2025, 10:57 AM
60 Degrees Pharmaceuticals Announces Clinical Site Now Open For Patient Enrollment In B-FREE Chronic Babesiosis Study At Mount Sinai Icahn School Of Medicine
📈 PositiveBenzinga•Nov 21, 2025, 01:04 PM
HC Wainwright & Co. Assumes 60 Degrees at Buy, Announces Price Target of $6
📈 PositiveBenzinga•Nov 14, 2025, 12:48 PM
60 Degrees Q3 EPS $(0.66) Beats $(1.21) Estimate, Sales $437.602K Beat $400.000K Estimate
📈 PositiveBenzinga•Nov 13, 2025, 06:54 PM
60 Degrees Pharmaceuticals Says The First Patient Who Completed The Regimen In Expanded Access Study Of Arakoda (Tafenoquine) Combined With Conventional Treatments For Relapsing Babesiosis In Immunosuppressed Patients Has Tested Negative For Babesiosis
📈 PositiveBenzinga•Oct 15, 2025, 11:16 AM
60 Degrees Pharma Launches B-FREE Study, First-Ever Trial for Chronic Babesiosis Treatment
📈 PositiveBenzinga•Oct 9, 2025, 11:18 AM
Ascendiant Capital Maintains Buy on 60 Degrees, Lowers Price Target to $3
➖ NeutralBenzinga•Sep 3, 2025, 10:45 AM
60 Degrees Pharma Signs Clinical Trial Agreement With Icahn School Of Medicine At Mount Sinai In New York City As Central Site For Phase II Clinical Study Of Tafenoquine In Treating Chronic Babesiosis
📈 PositiveBenzinga•Aug 19, 2025, 12:56 PM
Frequently Asked Questions about SXTP
What is SXTP's current stock price?
60 Degrees Pharmaceuticals, Inc. (SXTP) is currently trading at $0.76 per share. The stock has moved -9.59% today.
What is the analyst price target for SXTP?
No analyst price targets are currently available for this stock.
What sector is 60 Degrees Pharmaceuticals, Inc. in?
60 Degrees Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SXTP's market cap?
60 Degrees Pharmaceuticals, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does SXTP pay dividends?
No, 60 Degrees Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBDRX
Biodexa Pharmaceuticals Plc
$3.64
Mkt Cap: $0.0B
CANF
Can-Fite BioPharma Ltd.
$0.25
Mkt Cap: $0.0B
CLDI
Calidi Biotherapeutics, Inc.
$1.36
Mkt Cap: $0.0B
CMND
Clearmind Medicine Inc.
$2.74
Mkt Cap: $0.0B
CNSP
CNS Pharmaceuticals, Inc.
$6.51
Mkt Cap: $0.0B
GRI
GRI Bio, Inc.
$0.34
Mkt Cap: $0.0B
JAGX
Jaguar Health, Inc.
$1.17
Mkt Cap: $0.0B
KZIA
Kazia Therapeutics Limited
$10.87
Mkt Cap: $0.0B
SILO
Silo Pharma, Inc.
$0.38
Mkt Cap: $0.0B
SNGX
Soligenix, Inc.
$1.38
Mkt Cap: $0.0B
Explore stocks similar to SXTP for comparison